title: Comparison of patients with juvenile psoriatic arthritis and nonpsoriatic juvenile idiopathic arthritis: how different are they?
abstract: OBJECTIVE
  To compare the clinical features and outcome between patients with juvenile psoriatic arthritis (JPsA) and non-JPsA juvenile idiopathic arthritis (JIA).
  
  
  METHODS
  Fifty-three children with JPsA, 32 with < 5 joints in the first 6 months of disease (oligo-JPsA) and 21 (> or = 5 joints) polyarticular-onset (poly-JPsA) were compared to 53 patients with JIA who were matched by sex, age, date of diagnosis, and articular onset pattern.
  
  
  RESULTS
  There was no difference in the percentage of patients between the oligoarticular groups who developed extended oligoarthritis or in the percentage of patients who were positive for antinuclear antibodies. The only differences were that 25% of patients with oligo-JPsA had dactylitis compared to 0% of patients with oligo-JIA (p < 0.01) and 50% had nail pitting as compared to 18.7% (p < 0.05). In polyarticular patients the percentages with dactylitis were similar (19% vs 38%; p = 0.25). The frequency of uveitis was identical in the oligoarticular patients but a higher rate was seen in poly-JPsA compared to poly-JIA (23.8% vs 0%; p = 0.02), while contractures were more frequent in poly-JIA compared to poly-JPsA during the course of the illness (47.6% vs 14.3%; p = 0.03) but not at last followup (14.3% vs 4.7%; p = 0.6). At last followup the mean Childhood Health Assessment Questionnaire scores were similar in both the polyarticular and oligoarticular groups.
  
  
  CONCLUSIONS
  There were only a few differences between patients with JPsA and JIA regarding disease onset, disease course, and outcome. We suggest that large, longterm prospective studies are required to accurately determine whether subdividing JIA according to psoriasis is worthwhile.
authors: Division of Rheumatology, Hospital for Sick Children, Toronto, Ontario, Canada.
authors: Yonatan Aviel
authors: YA
authors: Butbul
authors: Pascal N
authors: PN
authors: Tyrrell
authors: Rayfel
authors: R
authors: Schneider
authors: Sandeep
authors: S
authors: Dhillon
authors: Brian M
authors: BM
authors: Feldman
authors: Ronald M
authors: RM
authors: Laxer
authors: Rotraud K
authors: RK
authors: Saurenmann
authors: Lynn
authors: L
authors: Spiegel
authors: Bonnie
authors: B
authors: Cameron
authors: Shirley M
authors: SM
authors: Tse
authors: Earl D
authors: ED
authors: Silverman
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D015535:Arthritis, Psoriatic / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003937:Diagnosis, Differential; D018450:Disease Progression; D005260:Female; D006306:Health Surveys; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D008297:Male; D017063:Outcome Assessment, Health Care; D010641:Phenotype; D011379:Prognosis; D012737:Sex Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal